OBJECTIVE: To assess the influence of etanercept, an anti-tumour necrosis factor (TNF)-α agent, on autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors. METHODS: Patients with psoriasis underwent 5-min electrocardiogram (ECG) recordings before and after 24 weeks of etanercept therapy. Linear heart rate variability (HRV) analysis was performed. RESULTS: The study recruited 19 patients. Frequency-domain analysis showed a significant decrease in oscillatory components attributable to sympathetic activity (LF%) and a significant decrease in low frequency/high frequency (LF/HF) ratio following etanercept therapy. CONCLUSION: Treatment with etanercept in patients with moderate-to-severe psoriasis could affect cardiovascular autonomic regulation, and subsequently reduce cardiovascular risk.

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy. Prospective study / Potenza, Concetta; Raimondi, Gianfranco; Pampena, Riccardo; Proietti, Ilaria; LA VIOLA, Giorgio; Bernardini, Nicoletta; Tolino, Ersilia; Zuber, Sara; Balduzzi, V; Scordamaglia, Beatrice; Skroza, Nevena. - In: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. - ISSN 0300-0605. - 44:1(2016), pp. 43-47. [10.1177/0300060515593242]

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy. Prospective study.

POTENZA, Concetta;RAIMONDI, GIANFRANCO;PAMPENA, RICCARDO;PROIETTI, ILARIA;LA VIOLA, GIORGIO;BERNARDINI, NICOLETTA;TOLINO, ERSILIA;ZUBER, SARA;SCORDAMAGLIA, BEATRICE;SKROZA, Nevena
2016

Abstract

OBJECTIVE: To assess the influence of etanercept, an anti-tumour necrosis factor (TNF)-α agent, on autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors. METHODS: Patients with psoriasis underwent 5-min electrocardiogram (ECG) recordings before and after 24 weeks of etanercept therapy. Linear heart rate variability (HRV) analysis was performed. RESULTS: The study recruited 19 patients. Frequency-domain analysis showed a significant decrease in oscillatory components attributable to sympathetic activity (LF%) and a significant decrease in low frequency/high frequency (LF/HF) ratio following etanercept therapy. CONCLUSION: Treatment with etanercept in patients with moderate-to-severe psoriasis could affect cardiovascular autonomic regulation, and subsequently reduce cardiovascular risk.
File allegati a questo prodotto
File Dimensione Formato  
Potenza_Cardiovascular-risk_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 142.33 kB
Formato Adobe PDF
142.33 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/896615
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact